

## Supplementary Appendix for: Natural History of Untreated Pulmonary Tuberculosis in Adults: A Systematic Review and Meta-Analysis

Bianca Sossen (MBChB)<sup>1,2,#</sup>, Alexandra Richards (MMathPhys)<sup>3,4,#</sup>, Torben Heinsohn (BMBCh)<sup>2,5</sup>, Beatrice Frascella (MD)<sup>6</sup>, Federica Balzarini (MD)<sup>6</sup>, Aurea Oradini-Alacreu (MD)<sup>6</sup>, Prof. Anna Odone (PhD)<sup>7</sup>, Ewelina Rogozinska (PhD)<sup>8</sup>, Brit Häcker (Dr)<sup>9</sup>, Prof. Frank Cobelens (PhD)<sup>10,11</sup>, Prof. Katharina Kranzer (PhD)<sup>12-14</sup>, Prof. Rein MGJ Houben (PhD)<sup>3,4,&</sup>, Hanif Esmail (PhD)<sup>2,8,15;&¥</sup>

<sup>1</sup> Department of Medicine, Faculty of Health Sciences, University of Cape Town, South Africa

<sup>2</sup> Institute for Global Health, University College London, London, UK

<sup>3</sup> TB Modelling Group, TB Centre, London School of Hygiene and Tropical Medicine, London, UK

<sup>4</sup> Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Public Health, London School of Hygiene and Tropical Medicine, London, UK

<sup>5</sup> Helmholtz Centre for Infection Research, Department of Epidemiology

<sup>6</sup> School of Public Health, Vita-Salute San Raffaele University, Milan, Italy

<sup>7</sup> Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy

<sup>8</sup> MRC Clinical Trials Unit at University College London, UK

<sup>9</sup> German Central Committee against Tuberculosis (DZK), Berlin, German

<sup>10</sup> Amsterdam University Medical Centers location University of Amsterdam, Department of Global Health

<sup>11</sup> Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands

<sup>12</sup> Clinical Research Department, Faculty of Infectious and Tropical Disease, London School of Hygiene and Tropical Medicine, London, UK

<sup>13</sup> Biomedical Research and Training Institute, Harare, Zimbabwe

<sup>14</sup> Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany

<sup>15</sup> Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, South Africa

# Contributed Equally

& Contributed Equally

¥ Corresponding Author: Dr Hanif Esmail at MRC Clinical Trials Unit, 90 High Holborn, London, WC1V 6LJ or [h.esmail@ucl.ac.uk](mailto:h.esmail@ucl.ac.uk)

## Table of Contents

<b>Supplementary Table 1: Adapted Newcastle Ottawa Quality Assessment Tool.....</b>	<b>3</b>
<b>Supplementary Table 2: Bias Assessment.....</b>	<b>6</b>
<b>Supplementary Table 3: Extracted studies.....</b>	<b>7</b>
<b>Supplementary Table 4: Descriptors on imaging assessments.....</b>	<b>18</b>
<b>Supplementary Table 5: Descriptors of cohorts included in the Systematic Review.....</b>	<b>21</b>
<b>Supplementary Figure 1: Micro negative to positive, in those studies that used culture.....</b>	<b>23</b>
<b>Supplementary Figure 2: Micro negative to positive, stratified by symptom and CXR status at baseline. 24</b>	
<b>Supplementary Figure 3: CXR negative and Micro negative, to Micro positive.....</b>	<b>25</b>
<b>Supplementary Figure 4: Micro negative to positive, stratified by structure of follow up.....</b>	<b>26</b>
<b>Full Search Strategy: English.....</b>	<b>27</b>
<b>Full Search Strategy: German.....</b>	<b>29</b>
<b>PRISMA Checklist(39).....</b>	<b>30</b>
<b>References.....</b>	<b>32</b>

## Supplementary Table 1: Adapted Newcastle Ottawa Quality Assessment Tool

GENERAL QUALITY ASSESSMENT		MAXIMUM STARS
<b>STUDY SELECTION</b>		
1. Representativeness of 'exposed' cohort		
Truly representative of general population e.g. identified through prospective recruitment following mass screening or household screening		1 star
Somewhat representative of general population e.g. identified through occupational screening		
Selected group e.g. sanatorium or hospital patients		0 stars
No description of the derivation of the cohort		
2. Selection of non-exposed cohort		
<i>NOT APPLICABLE</i>		
3. Ascertainment of exposure*		
Documented TST conversion		1 star
Exposure appropriately inferred from significant exposure to active TB e.g. in household or occupational setting		
No clear significant exposure to active TB		0 stars
No description		
4. Demonstration that outcome of interest not present at start of study*		
Yes - evidence of TB excluded by CXR at beginning of follow-up, or documented as not being present on CXR within previous 12 months		1 star
Not stated		0 stars
<b>COMPARABILITY</b>		
<i>NOT APPLICABLE</i>		
<b>OUTCOME</b>		
5. Assessment of outcome		
Disease defined on the basis of microbiological demonstration of organism		1 star
Disease defined without microbiological evidence		0 stars
No description		
6. Could intervention prevent development of outcome		
No medical or surgical treatment provided		1 star
Medical or surgical treatment provided to a subgroup of clearly identified individuals analysed separately and no selection bias		
Medical or surgical treatment provided to a subgroup (<10%) and that treatment deemed unlikely to influence outcome		
Medical or surgical treatment provided to a large number of individuals OR unable to be analysed separately OR selection bias		0 stars
7. Was total follow-up long enough for outcomes to occur		
Yes - follow-up equal to or longer than 12 months		1 star
No		0 stars
8. Adequacy of follow-up of cohorts		
Complete follow-up		1 star
Participants lost to follow up unlikely to introduce bias: <20% of participants lost to follow-up per annum, or description provided for those lost, making introduction of bias unlikely		
Lost to follow-up rate > 20% per annum and no description of those lost		0 stars
No statement		

\* These sections were only applicable to those cohorts of patients that started with CXR and microbiology negative for TB

<b>ADDITIONAL SPECIFIC QUALITY ASSESSMENT</b> <i>- If study meets general quality criteria above, used to determine if microbiological, radiographic and symptoms are recorded to sufficient quality</i>		MAXIMUM STARS
<b>RADIOGRAPHY</b>		
<b>1. Technology</b>		
Radiography (X-Ray, Roentgenography)		1 star
Mass Miniature radiography (Photofluorography, Aburography)		
Other (please specify)		0 stars
<b>2. Diagnostic criteria used</b>		
Clear use of recognised diagnostic criteria (e.g. ATS)		1 star
Clear description of study specific methodology (not recognised diagnostic criteria)		
No or limited description of criteria or methodology		0 stars
No imaging		
<b>3. Methodology</b>		
Double or triple independent read		1 star
Single reader		0 stars
Not specified		
<b>4. Follow-up</b>		
Complete follow-up		1 star
<20% of participants per annum in follow-up did not receive imaging OR description for those not receiving imaging, making introduction of bias unlikely		
<80% followed up received imaging and no description of those lost		0 stars
No statement		
<b>MICROBIOLOGY</b>		
<b>1. Technology</b>		
Culture - solid		1 star
Culture - liquid		
Smear - with concentration		
Smear - without concentration		
Guinea pig inoculation		
Other (please specify)		
Not specified		0 stars
<b>2. Sampling method</b>		
24-hour sputum collection		1 star
48-hour sputum collection		
72-hour sputum collection		
Induced sputum (e.g. physiotherapy or saline)		
Spot sputum collection (including <24 hour collection)		
Gastric aspirate		
Nasal/Laryngeal/Tracheal swab		
Other (please specify)		
Not specified		0 stars
<b>3. Follow-up</b>		

Complete follow-up of those able to produce sputum	1 star
<20% of per annum of participants had sputum collected (of those able to produce) for microbiological investigation OR description provided for that lost, making introduction of bias unlikely	
Follow-up rate <80% and no description of those lost	0 stars
No statement	
<b>SYMPTOMS</b>	
<b>1. Methodology</b>	
Standardised symptom screen described in methodology	1 star
Clear statement of symptomatic vs asymptomatic	
Standardised definitions from published criteria used with symptoms included in definition	
No clear statement	0 stars
<b>2. Follow-up</b>	
Complete follow-up	1 star
<20% of participants per annum in follow-up did not get symptom assessment OR description provided for those lost, making introduction of bias unlikely	
Follow-up rate <80% and no description of those lost	0 stars
No statement	

## Supplementary Table 2: Bias Assessment

	General Quality Assessment†		Specific Quality Assessment		
	Study Selection‡	Outcome Assessment	Radiography	Microbiology	Symptoms
1. Alling(21)	0	000X	000X	00X	0X
2. Anastasatu(22)	X	0000	00XX	000	XX
3. Aneja(23)	0	0000	0000	000	00
4. Beeuwkes(24)	0	000X	00XX	00X	0X
5. Bobrowitz(25,26)	X	0000	0000	000	00
6. Borgen(27,28)	000	0000	000X	00X	00
7. Breu(29)	0	0000	000X	000	XX
8. Cowie(30)	0	0000	000X	000	XX
9. Downes(31)	X	000X	000X	XXX	00
10. Fridodt-Moller(32)	0	0000	0000	000	XX
11. Hong Kong Chest Service(33–36)	X	0000	000X	000	00
12. IUAT Committee on Prophylaxis(37)	X	0000	000X	000	XX
13. Lincoln(21,38)	0	000X	000X	00X	0X
14. Manser(39)	X	000X	000X	000	00
15. Marshall(40)	0	0000	0000	000	00
16. National Tuberculosis Institute(41–49)	000	0000	0000	000	XX
17. Norregaard(50)	X	0000	000X	000	0X
18. Okada(51)	00X	0000	0000	000	00
19. Orrego Puelma(52)	X	0000	000X	000	0X
20. Pamra(53)	0	0000	000X	000	XX
21. Puffer(54)	0	000X	000X	XXX	XX
22. Sikand(55)	000	000X	000X	000	XX
23. Styblo(56)	000	00XX	000X	00X	0X
24. Tuberculosis Society of Scotland(57,58)	X	0000	000X	000	XX

\* This table only includes the quality assessments for studies included in the meta-analysis, with a 0 representing a positive score and X representing a negative score.

† Studies could only lose two stars in the General Quality Assessment to proceed to data extraction. Further details of the quality assessment tools are available in supplementary material.

‡ Studies could score a maximum of 3 stars if participants entered the cohort with no evidence of disease (chest x-ray negative, microbiologically negative and asymptomatic) or a maximum of 1 star if participants already had some evidence of disease at entry.

## Supplementary Table 3: Extracted studies

	Population	Study Type	Dates of study	Imaging Assessment	Microbiological Assessment	Symptom Assessment	Follow up methods	Transition*	Proportion making transition (time, months)
<p><b>1. Alling(1)</b> (1955)</p> <p>USA</p>	<ul style="list-style-type: none"> <li>• Diagnosis of moderate tuberculosis</li> <li>• Followed up within the study hospital</li> <li>• Sourced from referral from private physician or mass occupational radiographic surveys</li> </ul>	Clinic/ Hospital/ Sanatorium Cohort	1938 - 1948	Chest X-ray (CXR) reviewed according to NTA <sup>+</sup> criteria with double, independent reading. All "moderate" tuberculosis at baseline	Sputum sent for unknown method. All deemed "arrested" in this data row.	Delineation of symptom status is not well defined but all individuals in this data row were deemed "arrested"	Retrospective collection of routinely collected clinical data from their hospital. Follow up was therefore not systematically done. Definitions of disease groups required repeat CXR and sputum testing over periods of time.	cxr.pos   micro.neg   sympt.unk [arrested#]  to  cxr.pos   micro.pos   sympt.unk	<ul style="list-style-type: none"> <li>• 8/58 (60)</li> <li>• 10/58 (60-156)</li> </ul>
<p><b>2. Anastasatu(2)</b> ) (1985)</p> <p>Romania</p>	Smear negative with minimal or moderately advanced pulmonary lesions	Control/ Placebo arm	Unkno wn	CXR	Sputum smear and culture	Not specified but described to be "without radioclinical symptoms of activity"	Follow up details not clear but authors describe follow up to 24 months, with sputum testing being performed	cxr.pos   micro.neg   sympt.neg  to  cxr.pos   micro.pos   sympt.unk	6/143 (24)
<p><b>3. Aneja(3)</b> (1979)</p> <p>India</p>	<ul style="list-style-type: none"> <li>• Symptomatic for TB and abnormal photofluorogram</li> <li>• Negative sputum microscopy</li> <li>• No TB treatment, or less than 2 weeks of treatment prior to entry into trial</li> <li>• Well enough for ambulant care</li> </ul>	Control/ Placebo arm	1968 - 1972	CXR that was double-read ± a third umpire in case of discrepancies	Sputum for microscopy and culture	Review of clinical symptoms e.g. cough	Repeat CXR and spot sputum for microscopy and culture were done at the end of the 2nd, 4th, 6th, 9th and 12th months of follow up	cxr.pos   micro.neg   sympt.pos  to  cxr.pos   micro.pos   sympt.unk	21/110 (12)
<p><b>4. Beeuwkes(4)</b> (1942)</p>	Household contacts with at least 6 months of follow up data	Household Contact Study	1933- 1938	CXR	72 hour concentrated sputum sample for microscopy. Some also had	Based on medical history and examination to have been "asymptomatic"	Re-examined 6-12 monthly plus additional unscheduled visits if	cxr.neg   micro.neg  symp.neg  to	1/784 (6-60)

USA					culture and/or inoculation.		developing symptoms. Reviews included medical history and examination, chest x-ray and sputum sampling.	cxr.unk   micro.pos   sympt.pos	
								cxr.neg   micro.neg   symp.neg	3/784 (6-60)
								to cxr.unk   micro.neg   sympt.pos	
								cxr.pos   micro.neg   sympt.neg	3/79 (6-60)
								to cxr.unk   micro.pos   sympt.pos	
								cxr.pos   micro.neg   sympt.neg	5/79 (6-60)
to cxr.unk   micro.neg   sympt.pos									
cxr.pos   . micro.neg   sympt.neg	13/43 (6-60)								
to cxr.unk   micro.pos   sympt.pos									
cxr.pos   micro.pos   sympt.pos	10/28 (6-60)								
to cxr.unk   micro.neg   sympt.unk									
<b>5. Bobrowitz(5, 6)</b> (1947; 1949) USA	<ul style="list-style-type: none"> <li>Patients at study site with minimal disease on Chest X-ray</li> <li>At least 6 months of follow up data</li> </ul>	Clinic/ Hospital/ Sanatorium Cohort	1938 - 1945	CXR	Sputum sample or gastric concentrates or cultures (authors noted that gastric cultures became more frequent	Symptoms and clinical review	Radiographic, mycobacteriological and clinical review during Sanatorium stay but intervals not clearly defined	cxr.pos   micro.neg   sympt.unk	26/191 (60)
								to cxr.pos   micro.pos   sympt.unk	



					from 1939 onwards)					
6. <b>Borgen(7,8)</b> (1951;1952)  Norway	<ul style="list-style-type: none"> <li>• Age: &gt;15 years</li> <li>• Factory workers who participated in a repeat survey</li> </ul>	Occupational/ Student Screening	1947 - 1949	Photofluorography: no lesion versus suggestive tuberculous lesion	It is unclear whether systematic sputum testing was done at baseline, irrespective of photofluorography results	Clinical review including symptoms such as loss of weight and signs such as pyrexia	Factory workers had repeat survey at 2 years follow up point. Included repeat photofluorography. Also included sputum testing but unclear as to whether this was performed in all or only those with radiographic abnormalities.	cxr.neg   micro.unk   sympt.unk	4/6884 (30)	
								to		cxr.pos   micro.pos   sympt.pos
								cxr.pos   . micro.neg   sympt.pos		to
								cxr.pos   micro.pos   sympt.pos		
								to	2/120 (30)	
								cxr.pos   micro.neg   sympt.neg		
								to		
								cxr.pos   micro.pos   sympt.pos		
7. <b>Breu(9)</b> (1954)  Germany	<ul style="list-style-type: none"> <li>• Patients that were assessed as part of mass screening in Ludwigsburg, Germany</li> <li>• Demonstrated abnormal chest X-ray at baseline but micro negative</li> </ul>	General Community Survey	1949 - 1952	Photofluorography, CXR, tomography	Sputum for culture if either symptomatic or CXR abnormality suggestive of TB (but not all patients were able to produce sputum)	Delineation of symptom status is not well defined. All patients had an ESR performed at baseline.	Followed up "regularly" but interval not specified. Follow up included CXR, CT, microbiology (for sputum, laryngeal swab, gastric lavage)	cxr.pos   micro.pos   sympt.unk	48/904 (3-48)	
								to		
								cxr.pos   micro.pos   sympt.unk		
8. <b>Cowie(10)</b> (1985)  South Africa	<ul style="list-style-type: none"> <li>• New or enlarging apical lesions on 6-monthly Chest X-ray occupational screening</li> <li>• Apical lesion still present on repeat Chest X-ray 2 months later</li> <li>• Concentrated smear X3 (baseline) and culture X2 (2-months later) of sputum was</li> </ul>	Occupational/ Student Screening	1979 - 1984	CXR with new or enlarging apical lesions	Early morning sputa for concentrated microscopy and culture	The authors do not comment on the clinical status/symptoms of the cohort	<ul style="list-style-type: none"> <li>• 3-monthly CXRs for 3 years followed by 6-monthly until 5 year endpoint in the study</li> <li>• Sputum for smear or culture if there was any progression radiographically or if the original lesion was thought to suggest bacteriologically positive disease</li> <li>• Histology from</li> </ul>	cxr.pos   micro.neg   sympt.unk	88/152 (3-58)	
								to		
								cxr.pos   micro.pos   sympt.unk		

	negative for MTB • Employee at the Gold Mine						bronchoscopy was also performed in some		
<b>9. Downes(11)</b> (1938)  USA	<ul style="list-style-type: none"> <li>Resident of Cattaraugus County</li> <li>Diagnosed with active TB at some stage during the cohort years</li> </ul>	Clinic/ Hospital/ Sanatorium Cohort	1923 - 1935	CXR	Microscopy on sputum (to confirm certain definitions, sputum was also concentrated)	Met the criteria for 'active' disease which was based on symptoms and examination	Retrospective data collection of clinical records, sanatoria outcomes and self-reporting. Data collection included that of mycobacteriology, clinical status and imaging.	cxr.pos   micro.pos   sympt.pos  to  cxr.pos   micro.neg   sympt.neg	<ul style="list-style-type: none"> <li>27/342 (12)</li> <li>104/342 (24)</li> <li>140/342 (36)</li> <li>158/342 (48)</li> <li>171/342 (60)</li> </ul>
<b>10. Frimodt-Moller(12)</b> (1965)  India	<ul style="list-style-type: none"> <li>Abnormalities on Chest X-ray at baseline (and deemed probably tuberculous aetiology by two reviewers)</li> <li>Negative smear and culture from sputum and laryngeal swab</li> </ul>	Control/ Placebo arm	1960-1961	CXR deemed probably tuberculous by two readers	Microscopy and culture of sputum and laryngeal swab	Delineation of symptom status is not well-defined	3-monthly follow-ups occurred over a 3 year period including CXR and microbiological assessment	cxr.pos   micro.neg   sympt.unk  to  cxr.pos   micro.pos   sympt.unk	<ul style="list-style-type: none"> <li>11/86 (12)</li> <li>18/86 (24)</li> <li>25/86 (36)</li> </ul>
<b>11. Hong Kong Chest Service(13-16)</b> (1979, 1981, 1981, 1984)  HONG KONG	<ul style="list-style-type: none"> <li>Age: 15-75 years</li> <li>Radiographic evidence of 'active pulmonary tuberculosis' by a Hong Kong Chest Physician (not those considered fibrotic/inactive)</li> <li>No previous ATT</li> <li>At least 5 sputum smears negative over approximately one week</li> </ul>	Control/ Placebo arm	Not specified	CXR	Microscopy and culture of sputum X 5	Cough, sputum production, haemoptysis	<ul style="list-style-type: none"> <li>1-2 sputum specimens for microscopy and culture at monthly reviews in the first year and then quarterly reviews up to 30 months</li> <li>20 CXRs done between baseline and month 60</li> <li>Clinical reports made at each sampling/imaging visit</li> <li>Unscheduled additional reviews</li> </ul>	cxr.pos   micro.neg   sympt.mixed  to  cxr.pos   micro.pos   sympt.unk	<ul style="list-style-type: none"> <li>40/176 (3)</li> <li>49/176 (6)</li> <li>61/176 (12)</li> <li>67/176 (18)</li> <li>69/176 (24)</li> <li>70/176 (30)</li> <li>71/176 (36)</li> <li>71/176 (60)</li> </ul>

							with imaging & sputum sampling occurred if deterioration suspected		
<b>12. IUAT Committee on Prophylaxis(17)</b> (1982) Europe	<ul style="list-style-type: none"> <li>Fibrotic lesions on Chest X-ray that had been stable during the year prior to study entry</li> <li>Positive Mantoux</li> <li>No previous ATT</li> <li>Not previously mycobacteriologically positive and not culture positive at entry to the trial</li> </ul>	Control/ Placebo arm	Unkn wn	CXR showing fibrotic lesions	2 Sputum cultures at entry	Not well-defined	<ul style="list-style-type: none"> <li>Annual reviews were done for 5 years including sputum culture, CXR and/or vital status was recorded</li> <li>Records were also reviewed annually to see whether participants had been started on TB treatment</li> </ul>	cxr.pos   micro.neg   sympt.unk  to  cxr.pos   micro.pos   sympt.unk	97/6990 (12-60)
<b>13. Lincoln(18)</b> (1954) USA	<ul style="list-style-type: none"> <li>No history of prior diagnosis of TB</li> <li>Now Chest X-ray suggestive of minimal TB</li> <li>Followed up within the study hospital for at least one year</li> <li>Sourced from referral from private physician (due to symptoms or a known TB contact) or from mass occupational radiographic surveys</li> </ul>	Clinic/ Hospital/ Sanatorium Cohort	1937 - 1947	CXR reviewed according to NTA criteria with double, independent reading. All "minimal" tuberculosis at baseline in this data row.	Sputum sent for unknown method. 128/134 had sputum examination for tubercle bacilli. 112/128 had at least one "positive" sputum by some method.	The authors' definition of 'active' disease makes use of the NTA definitions which include symptom activity within their definitions. The majority of those with 'active' disease were also noted to have self-presented for care rather than having being picked up during general community screening.	Retrospective collection of routinely collected clinical data from their hospital. Follow up was therefore not systematically done. Definitions of disease groups required repeat CXR and sputum testing over periods of time.	cxr.pos   micro.mixed   sympt.pos  to  cxr.pos   micro.neg   sympt.unk  to  cxr.pos   micro.pos   sympt.unk	<ul style="list-style-type: none"> <li>45/134 (24)</li> <li>71/134 (36)</li> <li>80/134 (48)</li> <li>83/134 (60)</li> <li>86/134 (72)</li> <li>87/134 (84)</li> </ul> <ul style="list-style-type: none"> <li>15/314 (24)</li> <li>25/314 (36)</li> <li>32/314 (48)</li> <li>35/314 (60)</li> <li>36/314 (72)</li> </ul>
<b>14. Manser(19)</b> (1953) Switzerland	<ul style="list-style-type: none"> <li>Patients from the study sanatorium's records</li> <li>Over 60 years of age</li> </ul>	Clinic/ Hospital/ Sanatorium Cohort	1941 - 1951	CXR	Sputum or gastric lavage for unspecified method	Symptom questioning, fever, temperature, weight; but the authors do not	Frequency of follow up was not specified, but included physical exam, weight, ESR, CXR/CT, and sputum or gastric lavage	cxr.pos   micro.pos   sympt.unk  to	15/40 (6)

						present breakdown of data		cxr.pos   micro.neg   sympt.unk		
<p><b>15. Marshall(20)</b> (1948)</p> <p>UK</p>	<ul style="list-style-type: none"> <li>• Acute bilateral pulmonary tuberculosis of presumably recent origin</li> <li>• Old-standing disease and disease with thick-walled cavities excluded</li> <li>• Bacteriologically proven</li> <li>• Unsuitable for collapse therapy</li> <li>• 15 to 30 years of age</li> </ul>	Control/ Placebo arm	1947 - 1948	CXR	Sputum (direct smear and culture) ± laryngeal swab or gastric lavage if unable to produce (for culture)	General condition, temperature, weight	<ul style="list-style-type: none"> <li>• All remained admitted to the sanatorium for 6 months and outcomes were assessed at this point</li> <li>• Follow up included monthly clinical reviews</li> <li>• CXR (by blinded radiologist) and mycobacterial investigations done by clinical team were recorded</li> </ul>	cxr.pos   micro.pos   sympt.pos to cxr.pos   micro.neg   sympt.unk	1/52 (6)	
<p><b>16. National Tuberculosis Institute</b>(21–28) (1974; 1976; 1976; 1976; 1978; 1978; 1978; 1978; 1982)</p> <p>India</p>	<ul style="list-style-type: none"> <li>• Randomly selected households in Bangalore district entered into a mass survey</li> <li>• Excluded those with BCG scars</li> </ul>	General Community Survey	1961 - 1968	CXR (this data row: normal or "considered to be of nontuberculous etiology")	Sputum (spot & overnight) for microscopy and culture in those with abnormal CXR or CXR not interpretable	The authors do not comment on the clinical status/symptoms of the cohort	Surveyed every 18-24 months including: <ul style="list-style-type: none"> <li>• Photofluorography</li> <li>• Two sputum specimens if any history of abnormal CXR or CXR not interpretable</li> </ul>	cxr.neg   micro.neg   sympt.unk	<ul style="list-style-type: none"> <li>• 44/31 490 (18)</li> <li>• 99/17 936 (60)</li> </ul>	
				CXR (this data row: "suggestive of tuberculous etiology")				cxr.pos   micro.neg   sympt.unk		<ul style="list-style-type: none"> <li>• 23/32 9(18)</li> <li>• 36/27 1 (60)</li> </ul>
				CXR				cxr.pos   micro.pos   sympt.unk		<ul style="list-style-type: none"> <li>• 86/26 9 (18)</li> <li>• 70/17 8 (36)</li> </ul>
<p><b>17. Norregaard(29)</b> (1990)</p> <p>Denmark</p>	<ul style="list-style-type: none"> <li>• Abnormal Chest X-ray</li> <li>• Sputum smear-negative</li> </ul>	Control/ Placebo arm	1978 - 1985	CXR	Sputum or gastric lavage for microscopy and culture X 6	Medical history: e.g. cough, haemoptysis, fever	CXR and culture of sputum or gastric lavage monthly for the first three months, followed by every second month	cxr.pos   micro.neg   sympt.mixed to cxr.pos   micro.pos   sympt.neg	6/28 (48)	

							for six months and annually thereafter for at least three years. In this data row: "slight or no symptoms" were deemed asymptomatic.	cxr.pos   micro.neg   sympt.mixed to cxr.pos   micro.pos   sympt.pos	2/28 (48)
<b>18. Okada(30)</b> (2012)  Cambodia	<ul style="list-style-type: none"> <li>&gt;10 years of age</li> <li>Living in survey area</li> <li>Two culture-negative specimens</li> </ul>	General Community Survey	2002 - 2004	CXR that was deemed "TB suggestive"	Sputum for smear and solid culture X 2	Medical history and examination	Reviewed TB registers for the development of incident TB cases	cxr.pos   micro.neg   sympt.neg to cxr.pos   micro.pos   sympt.pos	5/309 (1-24)
				Conducted a repeat review at 2 years of all those with abnormal CXR at baseline, including medical history, CXR and two sputum specimens for smear and culture			cxr.pos   micro.neg   sympt.neg to cxr.pos   micro.pos   sympt.unk	46/309 (24)	
				Reviewed TB registers for the development of incident TB cases			cxr.neg   micro.neg   sympt.neg to cxr.pos   micro.pos   sympt.unk	32/21580 (1-24)	
				Conducted a repeat review at 2 years of all those with abnormal CXR at baseline, including medical history, CXR and two sputum specimens for smear and culture			cxr.pos   micro.neg   sympt.neg to cxr.neg   micro.neg   sympt.unk	26/309 (24)	
<b>19. Orrego Puelma(31)</b> (1945)	<ul style="list-style-type: none"> <li>Abnormal CXR of minimal extent</li> <li>Had at least 2 years of follow up</li> </ul>	Clinic/Hospital/Sanatorium cohort	Unknwn	CXR	Sputum and/or gastric washings for microscopy,	Cough, loss of weight, haemoptysis, back pain	Repeat CXR and sputum testing were done at unspecified	cxr.pos   micro.neg   sympt.unk to	18/67 (24)

CHILE	data available for retrospective review				culture and/or inoculation		intervals over the two years	cxr.pos   micro.pos   sympt.unk	
20. Pamra(32) (1971)  India	<ul style="list-style-type: none"> <li>no history of previous treatment for Tb</li> <li>No manifest tuberculous lesion in any organ other than the lungs</li> <li>No evidence of diabetes or any other non-tuberculous disease</li> <li>Apparent radiological stability of the lesions during the period of observation before inclusion in the study, this period being not less than 3 months or more than 3 years</li> <li>Constantly negative results on direct smear and culture examination of at least 2 sputum and laryngeal swab specimens during the period of observation</li> </ul>	Control/ Placebo arm	1958 - 1968	CXR	At least 2 sputum and laryngeal swab specimens smear and culture negative	Not well-described	<ul style="list-style-type: none"> <li>Laryngeal swab culture and CXR were done 3-monthly during year 1</li> <li>Laryngeal swab culture and CXR were done 6-monthly during year 2-5</li> </ul>	cxr.pos   micro.neg   sympt.neg	2/178 (72)
								to	
21. Puffer(33) (1945)  USA	<ul style="list-style-type: none"> <li>Following up at study clinic at the time of study</li> <li>Deemed to have "reinfection type" Tuberculosis</li> </ul>	Clinic/ Hospital/ Sanatorium cohort	1931 - 1943	CXR (in this data row, all deemed to have apical disease)	As per Opie criteria: "Arrested" or "Apparently arrested" is diagnosed when all symptoms have disappeared for a period of at least 6 months and the physical signs are those of	Review of "physical signs and/or symptoms"	Outcome for all study participants was assessed at 1 Jan 1943 irrespective of when they started in the study. It is not clear if follow up review was systematic or only based on routinely collected clinical data. In order to meet	cxr.pos   micro.neg   sympt.neg	9/261 (62)
				CXR				to	
								cxr.pos   micro.neg   sympt.neg [arrested#]	10/267 (62)

					<p>a healed lesion, the disease is regarded as arrested or, when some uncertainty still exists, the designation "apparently arrested" has been regarded as preferable. When the patient first comes under observation of the clinic, arrested lesions are not infrequently recognisable only by radiological examination, but are separable from "latent lesions" because they are known to have passed through a period of manifest disease with the usual symptoms of pulmonary tuberculosis. When, however, a tuberculous pulmonary lesion, recognised by roentgenographic examination, has been accompanied by no symptoms of the disease discoverable by inquiry, but is associated with physical signs of a</p>		<p>study definitions, follow up would have had to meet NTA criteria.</p>	<p>cxr.pos   micro.pos   sympt.pos</p>	
				CXR				<p>cxr.pos   micro.pos   sympt.pos</p> <p>to</p> <p>cxr.pos   micro.neg   sympt.neg</p>	92/384 (62)

					healed lesion, such as impaired resonance or diminished breath sound, it should be classified as arrested tuberculosis"				
22. Sikand(34) (1959)  India	Employed as police officer in study setting	Occupational/ Student Screening	1952 - 1958	CXR deemed 'inactive' tuberculosis or tuberculosis of 'doubtful activity'	Sputum or laryngeal swab for unknown method	Delineation of symptom status is not well defined	<ul style="list-style-type: none"> <li>• CXR repeated at two timepoints: <ul style="list-style-type: none"> <li>o 17 months and</li> <li>o 5-6 years</li> </ul> </li> <li>• Indications and regularity of mycobacteriological testing not clearly described</li> </ul>	cxr.pos   micro.neg   sympt.unk to cxr.pos   micro.pos   sympt.unk	38/319 (12)
				CXR deemed 'Negative' for TB				cxr.neg   micro.unk   sympt.unk to cxr.pos   micro.pos   sympt.unk	89/11268 (17-69)
								cxr.neg   micro.unk   sympt.unk to cxr.pos   micro.neg   sympt.unk	251/11268 (17-69)
23. Styblo(35) (1967)  Czechoslovakia	<ul style="list-style-type: none"> <li>• 15 years and older</li> <li>• Resident of study district</li> </ul>	General Community Survey	1961 - 1965	CXR with two blinded, independent reviewers	Microscopy of sputum and culture of sputum/laryngeal swabs on 1-3 occasions in all with symptoms or abnormal CXR and in a random selection not meeting these criteria	Clinical History	<ul style="list-style-type: none"> <li>• Reviewed monthly if hospitalised</li> <li>• If ambulatory, CXR annually ± bacteriology if symptomatic or CXR changes</li> </ul>	cxr.neg   micro.neg   sympt.neg to cxr.unk   micro.pos   sympt.pos	<ul style="list-style-type: none"> <li>• 17/73 000 (1-12)</li> <li>• 33/73 000 (1-24)</li> <li>• 49/73 000 (1-36)</li> <li>• 66/73 000 (1-48)</li> </ul>
							cxr.neg   micro.neg   sympt.neg to	<ul style="list-style-type: none"> <li>• 102/73000 (1-12)</li> </ul>	



								cxr.unk   micro.pos   sympt.unk	<ul style="list-style-type: none"> <li>• 123/7 3000 (1-24)</li> <li>• 168/7 3000 (1-36)</li> <li>• 175/7 3000 (1-48)</li> </ul>
<b>24.</b> <b>Tuberculosis</b> <b>Society of</b> <b>Scotland(36,</b> <b>37)</b> (1958, 1963)  SCOTLAND	<ul style="list-style-type: none"> <li>• Age: &gt;15 years</li> <li>• European</li> <li>• No bacilli on sputum smear or culture</li> <li>• Abnormal CXR but of “doubtful activity” with no cavitation</li> <li>• No known active extrapulmonary disease</li> <li>• Not pregnant/ recently post-partum</li> <li>• Not diabetic</li> </ul>	Control/ Placebo arm	1954 - 1959	CXR	Sputum, gastric lavage or laryngeal swab for microscopy and/or culture	Authors noted that “chest radiograph was the only important sign of disease”	<ul style="list-style-type: none"> <li>• 3-monthly reviews, including CXR, weight checks and ESR testing</li> <li>• Follow up sputum testing was done in all those able to produce a sputum sample; laryngeal swabs or gastric lavage was only done if deterioration suspected</li> </ul>	cxr.pos   micro.neg   sympt.neg  to  cxr.pos   micro.pos   sympt.unk	9/95 (24)

\* Start and end points are labeled with three characteristics or states including a Chest Xray status (i.e. cxr.neg or cxr.pos or cxr.unk), a microbiological status (i.e. micro.neg, micro.pos, micro.unk, or micro.mixed), and a symptom status (i.e. sympt.neg, sympt.pos, sympt.unk or sympt.mixed). In these states, “neg” denotes negative, “pos” denotes positive, “unk” denotes unknown and “mixed” denotes a mixed group.

† The National Tuberculosis Association (NTA) developed criteria for assigning a clinical status to individuals with tuberculosis(38). These criteria and nomenclature changed over time but generally included groups such as “apparently cured”, “arrested”, “apparently arrested”, “quiescent”, and “active”. The definition of these groups included radiographic, microbiological and clinical criteria over defined periods of time.

‡ This group were known to have been microbiologically positive on a prior occasion, then documented arrested disease, followed by a relapse

ATT=Antituberculosis Therapy; IUAT=International Union Against Tuberculosis; NTA=National Tuberculosis Association; UK=United Kingdom; USA=United States of America

## Supplementary Table 4: Descriptors on imaging assessments

Author (Publication Year) Country	Imaging Assessment	Descriptor/quoted text from study
<b>1. Alling (1955)</b> USA	Inactive	<p>"The clinical status of each person at the time of diagnosis was assessed on the basis of roentgenographic and bacteriologic data collected during the first six months following diagnosis...according to the Diagnostic Standards (1940 edition) published by the National Tuberculosis Association (NTA)."</p> <p>"Arrested: For six months or more prior to the anniversary, the patient's sputum has been free of acid-fast bacilli and his serial chest roentgenograms have been compatible with stable disease. When more than a year has elapsed between clinic examinations and the chest roentgenograms show a stable lesion, the patient is continued in the arrested category throughout the interim."</p>
<b>2. Anastasatu (1985)</b> Romania	Inactive	"A group with an X-ray lesion extension smaller than 10cm <sup>2</sup> and with no epidemiological risk [and]... no "radiological activity"
<b>3. Aneja (1979)</b> India	Active	<p>"They had an abnormal shadow on a chest photofluorogram, read as pulmonary tuberculosis (TBP) by the Medical Officer"</p> <p>"suspected to have active tuberculosis on X-ray evidence on single 70mm photofluorogram"</p>
<b>4. Beeuwkes (1942)</b> USA	Mixed	<p>"Latent (asymptomatic) lesions of first infection or childhood type were designated as calcified nodules, and latent infiltrations, childhood; latent lesions of reinfection or adult type, as latent apical tuberculosis."</p> <p>"Latent (asymptomatic) infiltrations of either the childhood or adult type could be active (progressive or retrogressive), but they were classified as asymptomatic until the patient had symptoms, or physical signs of disease were demonstrated. At that time the diagnosis was changed to manifest (clinical) disease."</p>
	Active	Manifest (clinical) tuberculosis, that which gives rise to physical signs or symptoms or both, was designated as childhood (first infection type) or adult (reinfection type) depending on the usual anatomical and clinical characteristics of the lesion
<b>5. Bobrowitz (1947; 1949)</b> USA	Mixed	"Only patients with minimal tuberculosis according to the classification of the National Tuberculosis Association and with the characteristic roentgenological picture of pulmonary tuberculosis of the reinfection type were acceptable. These cases were further subdivided into four groups, according to the size of the infiltrations, In grouping the patients by type of lesion, we utilized the excellent definitions for the roentgenological character of the infiltration described by Reisner and Downes - Exudative, Productive and fibrotic, Exudative-productive, Fibro-calcific form"
<b>6. Borgen (1951;1952)</b> Norway	Active	"Cases submitted to control examination [were] grouped according to roentgenographic and clinical findings into 10 categories including: Active non-destructive tuberculous pulmonary lesions - This group includes cases with pulmonary infiltrates which, according to the roentgenographic findings (soft, indistinct parenchymal lesions) and clinical findings (elevated temperature, increased sedimentation rate, loss of weight, etc.) were considered active lesions but where direct smears or culture failed to reveal tubercle bacilli in the sputum and after an observation period of 1.5-3.5 years no other etiology could reasonably be assumed."
	Inactive	"Inactive pulmonary lesions - This group includes cases with clear-cut, dense, streak-formed and, sometimes calcified lesions. In these cases the process showed no signs of activity during the observation period"
<b>7. Breu (1954)</b> Germany	Mixed	<p>"Bewusst beschränke ich mich bei der Aufzeigung der Entwicklungsreihen aus der geschlossenen in die bakteriologisch offene Tuberkulose, bzw. auf die angeführten röntgenologischen Erscheinungsformen (=Ia-b-Fälle der Fürsorgestatistik)..."; "nur [...] als Ic/Ila angesprochenen Tuberkulosefälle [...], die sich später zu einer ansteckenden Lungentuberkulose entwickelten."</p> <p><i>Intentionally, in presenting the progression from closed to bacteriological open tuberculosis, meaning the roentgenological appearances (Ia-b-cases of the register); only as Ic/Ila classified cases that later progressed to a contagious tuberculosis. [According to old German tuberculosis classification, where Ia/b open, active on xray and contagious with or without bacteriology; Ic open, active but not contagious, with fuzzy appearance on xray; Ila closed, inactive with clear demarcation of lesion on xray]</i></p>
<b>8. Cowie (1985)</b>	Active	"New or enlarging apical lung lesions detected by routine 6-monthly chest radiography"

South Africa		
<b>9. Downes (1938)</b> USA	Active (Also micro pos)	Retrospectively captured imaging findings, based on clinical records
<b>10. Frimodt-Moller (1965)</b> India	Active	Cases showing lung pathology on the survey films according to two independent readers were referred for bacteriological examination in the field with laryngeal swab cultures and sputum collection for microscopy and sputum culture as well as for having another 70 mm X-ray film taken. The new film was compared with the former and cases thought to be of a non-tuberculous aetiology, or had only calcified lesions, were excluded. Other cases were ranked according to extent of the parenchymal lesion The pretreatment films of the cases have for the purpose of this report been re-read and classified by the senior author with regard to extent of disease and cavitation according to the pattern of classification used by Fox and Sutherland (1956). The assessor did not know what treatment had been given or the fate of the individual cases studied.
<b>11. Hong Kong Chest Service (1979(13), 1981(14), 1981(15), 1984(16))</b> HONG KONG	Active	"Patients admitted to the study...were diagnosed at the regular routine meetings of physicians of the Hong Kong Chest Service as having radiologically active pulmonary tuberculosis, not previously treated"
<b>12. IUAT Committee on Prophylaxis (1982)</b> Europe	Inactive	"For the purpose of entry to the trial, fibrotic lesions were defined as well-delineated radiographic lesions of probable tuberculous origin, usually in the upper half of the lung, which had been stable during the year prior to entry"
<b>13. Lincoln (1954)</b> USA	Inactive	"A review was made of all original diagnoses of minimal pulmonary tuberculosis made by the hospital staff during the years 1937 through 1947. In no case had a diagnosis of pulmonary tuberculosis been previously made" "Two physicians, independently of one another and without knowledge of the subsequent clinical course, classified the diagnostic chest roentgenogram of each case according to the presence of pulmonary tuberculosis and the stage of disease. The classification of the stage of disease was based on the Diagnostic Standards (1940 edition), published by the National Tuberculosis Association (NTA). In the few cases in which there was disagreement, consultation was held to effect a mutually acceptable decision." "Arrested: For six months or more prior to the anniversary, the patient's sputum has been free of acid-fast bacilli and his serial chest roentgenograms have been compatible with stable disease. When more than a year has elapsed between clinic examinations and the chest roentgenograms show a stable lesion, the patient is continued in the arrested category throughout the interim."
<b>14. Manser (1953)</b> Switzerland	Active (Also micro pos)	Retrospectively captured imaging findings, based on clinical records
<b>15. Marshall (1948)</b> UK	Active (Also micro pos)	Study included patients with acute bilateral pulmonary tuberculosis of presumably recent origin, and patients who were unsuitable for collapse therapy. Old-standing disease and disease with thick-walled cavities excluded. Xrays were reviewed by a blinded radiologist.
<b>16. National Tuberculosis Institute (1974; 1976; 1976; 1976; 1978; 1978; 1978; 1978; 1982)</b> India	Active	"Suggestive of tuberculous aetiology judged to be possibly, probably or definitely active tuberculous"
<b>17. Norregaard (1990)</b> Denmark	Active	"The admission criteria were usually small X-ray shadows compatible with active pulmonary tuberculosis in smear negative patients. This evaluation was made at conference by the consultants.... All patients had infiltrates in the upper lobe of one or both lungs"

<b>18. Okada (2012)</b> Cambodia	Active	"A panel of experts composed of two respiratory physicians and/or radiologists made a decision on the final radiological findings. Based on the Japanese CXR classification for TB" "A CXR suggestive of active TB was categorised as 'TB-suggestive CXR'"
<b>19. Orrego Puelma (1945)</b> CHILE	Mixed	"Minimum or superficial lesions without apparent cavity, limited to a small area in one or both lungs. The total involvement, ignoring its distribution, should not exceed the equivalent in volume of the lung tissue which lies above the second chondrosternal junction and the spine of the fourth or body of the fifth thoracic vertebra on one side." "Furthermore, we studied only those cases which had two years' evolution, at least."
<b>20. Pamra (1971)</b> India	Mixed	(a) No history of previous treatment for tuberculosis. (b) No manifest tuberculous lesion in any organ other than the lungs. (c) No evidence of diabetes or any other non-tuberculous disease. (d) Apparent radiological stability of the lesions during the period of observation before inclusion in the study, this period being not less than 3 months or more than 3 years.
<b>21. Puffer (1945)</b> USA	Mixed	"persons with lesions demonstrable by X-ray examination had no physical signs nor symptoms and gave no history of illness indicative of tuberculosis, they are classed as latent apical cases" "The classification of lesions as minimal, moderately advanced and far advanced is in accordance with that recommended by the National Tuberculosis Association."
	Inactive	"manifest cases were believed to be arrested at the time of first examination in this clinic." "The classification of lesions as minimal, moderately advanced and far advanced is in accordance with that recommended by the National Tuberculosis Association."
<b>22. Sikand (1959)</b> India	Inactive	Inactive Pulmonary Lesions (i) Sputum negative by all methods or L. S. negative by culture; (ii) Hardish shadows in the skiagrams; (iii) No clinical or laboratory evidence suggestive of activity.
	Mixed	Lesions of Doubtful Activity (i) Small soft infiltrations, stationary of regressive but not progressive; (ii) Primary type of tuberculosis; (iii) Known pulmonary cases under successful therapy.
<b>23. Styblo (1967)</b> Czechoslovakia	N/A	Xray negative group
<b>24. Tuberculosis Society of Scotland (1958, 1963)</b> SCOTLAND	Mixed	"Patients were accepted for the trial if the chest radiograph showed an abnormality considered to be tuberculous, this being the only important sign of disease" "certain conditions also excluded acceptance- ... cavitation demonstrable on an ordinary posteroanterior radiograph" "The clinicians were asked to classify their cases as 'acute' without evidence of fibrosis, or 'chronic', with fibrosis present."

Supplementary Table 5: Descriptors of cohorts included in the Systematic Review

	n (%) or median (IQR)
<b>Cohort Types, n=34</b>	
• Clinical Cohort	9 (24.5)
• Control arm of therapeutic intervention	9 (24.5)
• General Community Survey	7 (20.6)
• Household Contact Study	4 (11.8)
• Occupational or Student Screening	5 (14.7)
<b>Study Location, n=34</b>	
• Africa	1 (2.9)
• Asia	11 (32.4)
• Europe	10 (29.4)
• South America	1 (2.9)
• North America	11 (32.4)
<b>Status at entry to cohorts, n=34</b>	
• Normal Chest X-ray/imaging	4 (11.8)
• Abnormal Chest X-ray/imaging	30 (88.2)
○ Abnormal Chest X-ray/imaging, where the authors state that the extent of disease was active	15 (44.1)
○ Abnormal Chest X-ray/imaging, where the authors state that the extent of disease was inactive/fibrotic	9 (26.5)
○ Abnormal Chest X-ray/imaging, where the authors state that the extent of disease was “mixed” in this group or they did not describe/specify	6 (17.6)
• Microbiological status <sup>†</sup> negative	28 (82.4)
• Microbiological status <sup>†</sup> positive	6 (17.6)
• Microbiological status <sup>†</sup> mixed or unknown	0 (0.0)
• Symptomatic <sup>‡</sup>	7 (20.6)
• Asymptomatic <sup>‡</sup>	11 (32.4)
• Symptom status <sup>†</sup> mixed or unknown	16 (47.1)
<b>Demographics, n=34</b>	
• Sex distribution	
○ Equal distribution of males and females	5 (14.7)
○ More females	8 (23.5)
○ More males	11 (32.4)
○ Unknown sex distribution	10 (29.4)
• Age distribution	
○ Minimum	5 years
○ Maximum	83 years
○ No details on age distribution specified	10 (29.4)
<b>Local Burden of TB Disease at time of cohort<sup>§</sup>, n=34</b>	
• Low	0 (0.0)
• Mid	2 (5.9)
• High	9 (26.5)
• Not specified or unknown	23 (67.6)

\* Studies were able to contribute  $\geq 1$  cohort

† To establish microbiological status, authors used a variety of methods which included sputum (spot or extended collection periods e.g. overnight), laryngeal swabs, and gastric aspirates


‡ Symptom status was as per author classification

§ As per World Health Organisation stratification



IQR = Interquartile Range; TB = Tuberculosis



**Cohorts progressing to bacteriologically positive disease  
All studies using culture for bacteriological testing**




Supplementary Figure 1: Micro negative to positive, in those studies that used culture





Supplementary Figure 2: Micro negative to positive, stratified by symptom and CXR status at baseline





Supplementary Figure 3: CXR negative and Micro negative, to Micro positive



Supplementary Figure 4: Micro negative to positive, stratified by structure of follow up

## Full Search Strategy: English

### Filters to be applied within each:

- Languages: English, German & "Unknown language" (latter possible in Pubmed)
- Years: 1895 - 1960

#### a) Pubmed, Medline and Old Medline

	Category	Search terms
<b>ENGLISH</b>	<b>Population:</b>	Pulmonary tuberculosis OR "Tuberculosis, Pulmonary"[Mesh] OR Incipient tuberculosis OR Phthisis OR Minimal tuberculosis OR Moderate tuberculosis OR Advanced tuberculosis
	<b>Intervention:</b>	Follow up studies OR Course OR Biological Evolution OR After-history OR Supervision OR "Early Diagnosis"[Mesh] OR "Epidemiological Study"[Mesh] OR Epidemiologic study OR Prognosis OR Prospective OR Longitudinal OR Roentgenographic Survey OR Radiography OR Observation OR Progression OR Progress OR Diagnosis

(((((("tuberculosis, pulmonary"[MeSH Terms] OR ("tuberculosis"[All Fields] AND "pulmonary"[All Fields]) OR "pulmonary tuberculosis"[All Fields] OR ("pulmonary"[All Fields] AND "tuberculosis"[All Fields])) OR "Tuberculosis, Pulmonary"[Mesh]) OR (Incipient[All Fields] AND ("tuberculosis"[MeSH Terms] OR "tuberculosis"[All Fields]))) OR ("tuberculosis, pulmonary"[MeSH Terms] OR ("tuberculosis"[All Fields] AND "pulmonary"[All Fields]) OR "pulmonary tuberculosis"[All Fields] OR "phthisis"[All Fields])) OR (Minimal[All Fields] AND ("tuberculosis"[MeSH Terms] OR "tuberculosis"[All Fields]))) OR (Moderate[All Fields] AND ("tuberculosis"[MeSH Terms] OR "tuberculosis"[All Fields]))) OR (Advanced[All Fields] AND ("tuberculosis"[MeSH Terms] OR "tuberculosis"[All Fields]))) AND (((((((((((("follow-up studies"[MeSH Terms] OR ("follow-up"[All Fields] AND "studies"[All Fields]) OR "follow-up studies"[All Fields] OR ("follow"[All Fields] AND "up"[All Fields] AND "studies"[All Fields]) OR "follow up studies"[All Fields]) OR Course[All Fields]) OR ("biological evolution"[MeSH Terms] OR ("biological"[All Fields] AND "evolution"[All Fields]) OR "biological evolution"[All Fields])) OR After-history[All Fields]) OR ("organization and administration"[MeSH Terms] OR ("organization"[All Fields] AND "administration"[All Fields]) OR "organization and administration"[All Fields] OR "supervision"[All Fields])) OR "Early Diagnosis"[Mesh]) OR ("epidemiologic studies"[MeSH Terms] OR ("epidemiologic"[All Fields] AND "studies"[All Fields]) OR "epidemiologic studies"[All Fields] OR ("epidemiologic"[All Fields] AND "study"[All Fields]) OR "epidemiologic study"[All Fields])) OR ("prognosis"[MeSH Terms] OR "prognosis"[All Fields])) OR ("longitudinal studies"[MeSH Terms] OR ("longitudinal"[All Fields] AND "studies"[All Fields]) OR "longitudinal studies"[All Fields] OR "prospective"[All Fields])) OR Longitudinal[All Fields]) OR (Roentgenographic[All Fields] AND ("surveys and questionnaires"[MeSH Terms] OR ("surveys"[All Fields] AND "questionnaires"[All Fields]) OR "surveys and questionnaires"[All Fields] OR "survey"[All Fields])) OR ("diagnostic imaging"[Subheading] OR ("diagnostic"[All Fields] AND "imaging"[All Fields]) OR "diagnostic imaging"[All Fields] OR "radiography"[All Fields] OR "radiography"[MeSH Terms])) OR ("observation"[MeSH Terms] OR "observation"[All Fields])) OR ("disease progression"[MeSH Terms] OR ("disease"[All Fields] AND "progression"[All Fields]) OR "disease progression"[All Fields] OR "progression"[All Fields])) OR Progress[All Fields]) OR ("diagnosis"[Subheading] OR "diagnosis"[All Fields] OR "diagnosis"[MeSH Terms])) AND ((("1895/01/01"[PDAT] : "1960/12/31"[PDAT]) AND (Undetermined[lang] OR German[lang] OR English[lang]))

b) EMBASE and EMBASE CLASSIC

	Category	Search terms
ENGLISH	<b>Population:</b>	“Pulmonary tuberculosis” OR “Incipient tuberculosis” OR Phthisis OR Minimal tuberculosis OR Moderate tuberculosis OR Advanced tuberculosis
	<b>Intervention:</b>	“Follow-up stud*” OR “Follow up stud*” OR Course OR “Biological Evolution” OR “After-history” OR Supervision OR Epidemiological Stud* OR Epidemiology OR Prognosis OR Prospective OR Longitudinal OR “Roentgenographic survey” OR Radiography OR Observation* OR Progress* OR Diagnosis

c) Web of Science

	Category	Search terms
ENGLISH	<b>Population:</b>	“Pulmonary tuberculosis” OR “Incipient tuberculosis” OR Phthisis OR Minimal tuberculosis OR Moderate tuberculosis OR Advanced tuberculosis
	<b>Intervention:</b>	“Follow up stud*” OR “Follow-up stud*” OR “Course” OR “Biological Evolution” OR “After-history” OR Supervision OR “Epidemiological Stud*” OR Epidemiology OR Prognosis OR Prospective OR Longitudinal OR “Roentgenographic Survey” OR Radiography OR Observation* OR Progress* OR Diagnosis

## Full Search Strategy: German

### PUBMED

<b>GERMAN</b>	<b>Population:</b>	Pulmonale Tuberkulose OR Lungentuberkulose OR Lungen-Tuberkulose OR "Tuberkulose, pulmonal, pulmonale" [Mesh] OR anfangende Tuberkulose OR beginnende Tuberkulose OR Beginn der lungentuberkulose OR Fruehinfiltrat OR einsetzende Tuberkulose OR Schwindsucht  OR Phthisische Entwicklung* OR Initialherd* OR Tuberculosis inappercepta OR Spitzenschwielen OR Spitzenherd* OR begrenzte* OR Tuberkulinreihenpruefungen OR Lungenschwindsucht OR Entstehung OR Entwicklung*
	<b>Intervention:</b>	Längsschnittstudie OR Longitudinalstudie OR Verlaufsstudie OR Verlauf OR Entwicklung OR Verlauf OR Nachverfolgung OR Beobachtung OR Frühdiagnose OR Früherkennung OR "epidemiologische Studie" [Mesh] OR Prognose OR prospektiv OR vorausschauend OR longitudinal OR längsschnitt OR Röntgen OR röntgenographisch OR radiographisch OR radiologisch OR Beobachtung OR Betrachtung OR Folge OR Entwicklung OR Progression OR Fortschreitung OR Verlauf OR Fortschritt OR Diagnose

### EMBASE

<b>GERMAN</b>	<b>Population:</b>	"Pulmonale Tuberkulose" OR "Lungentuberkulose" OR "Lungen-Tuberkulose" OR "generalisierte Tuberkulose" OR "disseminierte Tuberkulose" OR "miliare Tuberkulose" OR "anfangende Tuberkulose" OR "beginnende Tuberkulose" OR "einsetzende Tuberkulose" OR Tuberk* OR Schwindsucht
	<b>Intervention:</b>	"Längsschnittstudie" OR "Längsschnitt-studie" OR "Longitudinalstudie" OR "Longitudinal-studie" OR "Verlaufsstudie" OR "Verlaufs-studie" OR Verlauf OR "Entwicklung" OR "Verlauf." OR "Nachverfolgung" OR Beobachtung OR epidemiologische Studie OR Epidemiologie OR Prognose OR Prospektiv OR Vorausschauend OR longitudinal OR längsschnitt OR "Röntgen" OR "röntgenographische Studie" OR "röntgenographische Untersuchung" OR "radiologische Studie" OR "radiologische Untersuchung" OR Radiologie OR Röntgen OR Beobachtung* OR Fortschritt* OR Diagnose

### Web of Science

<b>GERMAN</b>	<b>Population:</b>	"Pulmonale Tuberkulose" OR "Lungentuberkulose" OR "Lungen-Tuberkulose" OR "generalisierte Tuberkulose" OR "disseminierte Tuberkulose" OR "miliare Tuberkulose" OR "anfangende Tuberkulose" OR "beginnende Tuberkulose" OR "einsetzende Tuberkulose" OR Tuberk* OR Schwindsucht
	<b>Intervention:</b>	"Längsschnittstudie" OR "Längsschnitt- studie" OR "Longitudinalstudie" OR "Longitudinal-studie" OR "Verlaufsstudie" OR "Verlaufs-studie" OR "Verlauf" OR "Entwicklung" OR "Nachverfolgung" OR Beobachtung OR "epidemiologische Studie" OR Epidemiologie OR Prognose OR Prospektiv OR Vorausschauend OR longitudinal OR längsschnitt OR verlauf OR "Röntgen" OR "röntgenographische Studie" OR "röntgenographische Untersuchung" OR "radiologische Studie" OR "radiologische Untersuchung" OR Radiologie OR Röntgen OR Beobachtung* OR Fortschritt* OR Diagnose

## PRISMA Checklist(39)

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	3
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5-6
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	6,9
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	9
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	9
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	9
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	9 & Supplementary
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	9-10
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	10-11

Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	11
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	10
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	10-11
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.	12

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	27
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	11
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	13 (figure 2)
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	16-18 & Supplementary
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	14
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	Figure 3,4 & Supplementary
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	Figure 3,4 & Supplementary
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	N/A
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	Supplementary figures
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	25

Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	26
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	25-27
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	12

## References

1. Alling D, Bosworth E, Lincoln N. The after-history of pulmonary tuberculosis: V. Moderately Advanced Tuberculosis. *Am Rev Tuberc.* 1955;71(4):519–28.
2. Anastasatu C, Bercea O, Corlan E. Controlled clinical trial on smear negative, x-ray positive new cases, with the view to establishing if and how to treat them. *Bull Int Union Tub.* 1985;60:108–9.
3. Aneja KS, Gothi GD, Samuel GER. CONTROLLED STUDY OF THE EFFECT OF SPECIFIC TREATMENT ON BACTERIOLOGICAL STATUS OF ‘SUSPECT CASES.’ *Indian J Tuberc.* 1979;26:8.
4. Beeuwkes H, Hahn RG, Putnam P. A Survey of Persons Exposed to Tuberculosis in the Household<sup>1</sup>. *Am Rev Tuberc.* 1942;29.
5. Bobrowitz ID, Hurst A, Martin M. Minimal Tuberculosis; the prognosis and clinical significance of a sanatorium treated group. *Am Rev Tuberc.* 1947;56(2):16.
6. Bobrowitz ID, Hurst A. Minimal Tuberculosis: Problems in Roentgenologic Interpretation. *Radiology.* 1949 Apr;52(4):519–32.
7. Borgen L, Meyer S, Refsum E. Mass photofluorography, tuberculin testing, and BCG vaccination in the district of Aker (Norway) 1947-49. *Acta Tuberc Scand.* 1951;25(4):327–55.
8. Borgen L., Meyer SN., Refsum E. A preliminary report of tuberculin tests and mass chest surveys carried out in Aker. *Acta Tuberc Scand Suppl.* 1950;26:159–68.
9. Breu K. [Public health x-ray diagnosis of closed pulmonary tuberculosis later proved contagious]. *Beitrage Zur Klin Tuberk Spezifischen Tuberk-Forsch.* 1954;111(5):437–44.



10. Cowie L, Langton ME. Diagnosis of sputum smear- and sputum culture-negative pulmonary tuberculosis. SAMJ. 1985;68:1.
11. Downes J. A Study of Mortality among Individuals with Active Pulmonary Tuberculosis. Milbank Mem Fund Q. 1938 Jul;16(3):304.
12. Fridodt-Moller J, Parthasarathy R, Thomas J. Results of treatment of non-bacillary tuberculosis in a domiciliary treatment programme,-a preliminary report. 1960;
13. Hong Kong Chest Service. SPUTUM-SMEAR-NEGATIVE PULMONARY TUBERCULOSIS CONTROLLED TRIAL OF 3-MONTH AND 2-MONTH REGIMENS OF CHEMOTHERAPY. The Lancet. 1979 Jun;313(8131):1361-3.
14. Hong Kong Chest Service, Tuberculosis Research Centre, Mad, British Medical Research Council. A study of the characteristics and course of sputum smear-negative pulmonary tuberculosis. Tubercle. 1981 Sep;62(3):155-67.
15. Hong Kong Chest Service. A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum smear-negative pulmonary tuberculosis: the results at 30 months. 1981;
16. Hong Kong Chest Service, Centre TR. A Controlled Trial of 2-Month, 3-Month, and 12-Month Regimens of Chemotherapy for Sputum-Smear-Negative Pulmonary Tuberculosis: Results at 60 months. Am Rev Respir Dis. 1984;6.
17. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various duration of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Org. 1982;60(4):555-64.
18. Lincoln NS, Bosworth EB, Alling DW. The After-History of Pulmonary Tuberculosis - III: Minimal tuberculosis. Am Rev Tuberc. 1954;70(1):17.
19. Manser H. [Tuberculosis in aged and its course during sanatorium treatment]. Schweiz Z Tuberk Rev Suisse Tuberc Riv Svizzera Della Tubercosi. 1953;10(2):65-82.
20. Medical Research Council. Streptomycin Treatment of Pulmonary Tuberculosis: A Medical Research Council Investigation. BMJ. 1948 Oct 30;2(4582):769-82.
21. Chakarabarty, A K, Singh, H, Srikantan, K, Rangaswamy, K R, Krishnamurthy, MS, Stephen, J A. Tuberculosis in a rural population of South India: Report on five surveys. Indian J Tuberc. 1982;29(3):153-67.
22. Chakraborty, A K, Gothi, G D, Dwarkanath S, Singh H. Tuberculosis mortality rate in a South Indian rural population. Indian J Tuberc. 1978;25(3).
23. Krishnamurthy V, Nair S, Gothi G. A comparison of new cases (incidence cases) who had come from different epidemiological groups in the population. Indian J Tuberc. 1978;25(3).

24. Gothi GD, Chakaraborty AK, Jayalakshmi MJ. INCIDENCE OF SPUTUM POSITIVE TUBERCULOSIS IN DIFFERENT EPIDEMIOLOGICAL GROUPS DURING FIVE YEAR FOLLOW UP OF A RURAL POPULATION IN SOUTH INDIA. *Indian J Tuberc.* 1978;25(2):9.
25. Krishnamurthy VV, Nair SS, Gothi GD, Chakaraborty AK. Incidence of Tuberculosis among newly infected population and in relation to the duration of infected status. *Indian J Tuberc.* 1976;23(1).
26. Gothi, G D, Chakaraborty, A K, Ganapathy, K.T. Five year incidence of tuberculosis and crude mortality in relation to non-specific tuberculin sensitivity. *Indian J Tuberc.* 1976;23(2).
27. Chakaraborty AK, Gothi GD. RELAPSES AMONG NATURALLY CURED CASES OF PULMONARY TUBERCULOSIS. *Indian J Tuberc.* 1976;23(1):6.
28. Chakaraborty AK. INTERPRETATION OF PHOTOFLUOROGRAMS OF ACTIVE PULMONARY TUBERCULOSIS PATIENTS FOUND IN EPIDEMIOLOGICAL SURVEY AND THEIR FIVE YEAR FATE. *Indian J Tuberc.* 1974;21:8.
29. Norregaard J. Abacillary pulmonary tuberculosis. *Tubercle.* 1990;71:35–8.
30. Okada K, Onozaki I, Yamada N, Yoshiyama T, Miura T, Saint S, et al. Epidemiological impact of mass tuberculosis screening: a 2-year follow-up after a national prevalence survey. :7.
31. Orrego Puelma H, Grebe G. Analysis of One Hundred Cases of Minimal Pulmonary Tuberculosis. *Dis Chest.* 1945 Sep;11(5):375–9.
32. Pamra SP, Mathur GP. Effects of Chemoprophylaxis on Minimal Pulmonary Tuberculosis Lesions of Doubtful Activity. *Bull World Health Org.* 1971;45(5):10.
33. Puffer RR, Stewart HC, Gass RS. Tuberculosis according to age, sex, family history, and contact. *Am Rev Tuberc.* 1945;51(4):295–311.
34. Sikand B, Narrain R, Mathur G. Incidence of TB as Judged by Re-surveys. *Indian J Tuberc.* 1959;6:73–83.
35. Styblo K, Dajkova D, Kubik A, Langerova M, Radkovsky J. Epidemiological and Clinical Study of Tuberculosis in the District of Kolin, Czechoslovakia. *Bull World Health Org.* 1967;37:56.
36. Tuberculosis Society of Scotland. A controlled trial of chemotherapy in pulmonary tuberculosis of doubtful activity. *Tubercle.* 1958 Jun;39(3):129–37.
37. Scottish Thoracic Society. A controlled trial of chemotherapy in pulmonary tuberculosis of doubtful activity: Five year follow-up. *Tubercle.* 1963 Mar;44(1):39–46.

38. Long ER, Hopkins FD. History of Diagnostic Standards and Classification of Tuberculosis of the National Tuberculosis Association. *Am Rev Tuberc.* 1952 Apr;65(4):494–504.
39. Moher D, Liberati A, Tetzlaff J, Altman D, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLOS Med.* 6(7).